Alnylam Pharma (ALNY) Tops Q3 EPS by 15c, Misses on Revenue, Offers FY22 Revenue Guidance

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. AMGN
3. BKNG
4. DOX
5. DUOL
6. ANET
7. SWKS
8. XYZ
9. FISV
10. CVS

Go back to Alnylam Pharma (ALNY) Tops Q3 EPS by 15c, Misses on Revenue, Offers FY22 Revenue Guidance

Alnylam Pharmaceuticals Reports Third Quarter 2022 Financial Results and Highlights Recent Period Activity

October 27, 2022 8:00 AM EDT

Achieved Third Quarter 2022 Global Net Product Revenues of $232 Million for ONPATTRO®, AMVUTTRA®, GIVLAARI®, and OXLUMO®

Strong First Full Quarter of AMVUTTRA in U.S.: Achieving $25 Million in Net Product Revenues and Driving 30% U.S. Total TTR Growth Compared with Q2 2022

Reported Positive Results from the APOLLO-B Phase 3 Study of Patisiran, and Remains on Track for a Supplemental New Drug Application (sNDA) Submission in Late 2022

Reiterated 2022 Combined Net Product Revenue Guidance of $870-$930 Million

CAMBRIDGE, Mass.--(BUSINESS... More